Retatrutide: The Complete Guide to the Triple Agonist Peptide
Last updated: · Monthly refresh · Updated on every Phase 3 readout
28.7%
Body weight loss (Phase 3)
3
Receptors: GIP + GLP-1 + Glucagon
7
Phase 3 trials underway
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Medical disclaimer: This guide is for educational purposes only and is not medical advice. Retatrutide is an investigational compound not approved by the FDA. Always consult a qualified healthcare provider before starting any medication. See our full medical disclaimer.
In this guide
What is retatrutide?
Retatrutide (LY3437943) is an investigational obesity medication developed by Eli Lilly. It is a triple hormone receptor agonist — a single molecule that activates three distinct receptor pathways simultaneously: GLP-1, GIP, and glucagon.
That three-receptor approach is the central fact about retatrutide. Everything else follows from it.
Semaglutide (Wegovy, Ozempic) targets one receptor: GLP-1. It suppresses appetite and slows gastric emptying. Tirzepatide (Mounjaro, Zepbound) targets two: GLP-1 and GIP. The second receptor improves metabolic efficiency and is why tirzepatide outperforms semaglutide. Retatrutide adds a third: glucagon.
Glucagon receptor activation increases energy expenditure and promotes fat oxidation — particularly in the liver. Where GLP-1 reduces how much energy goes in and GIP improves how the body processes that energy, glucagon increases how much energy the body actually burns. Think of it as closing two valves and opening a drain at the same time.
Eli Lilly has been developing retatrutide since at least 2019. The compound entered Phase 1 trials in 2020, Phase 2 in 2021, and Phase 3 in 2023 under the TRIUMPH program. TRIUMPH now includes at least 7 trials across obesity, type 2 diabetes, MASH/NAFLD, sleep apnea, cardiovascular outcomes, and obesity with knee osteoarthritis.
For full compound data — dosage, mechanism, pharmacokinetics — see the retatrutide compound profile.
Clinical trial results
Phase 2: The data that started everything
The Phase 2 trial was published in the New England Journal of Medicine in July 2023 (PMID: 37385275). It enrolled 338 adults with obesity and ran for 48 weeks, testing multiple doses of retatrutide against placebo.
| Dose | Weight Loss at 48 Weeks | Notes |
|---|---|---|
| Placebo | -2.1% | Control group |
| 4 mg | -17.1% | Lowest active dose |
| 8 mg | -22.8% | Mid-range dose |
| 12 mg | -24.2% | Highest dose — largest trial-reported weight loss at the time |
The 24.2% figure was, at the time of publication, the largest average weight loss ever recorded in a controlled clinical trial. For context: semaglutide produced 14.9% in STEP 1 (PMID: 33567185). Tirzepatide produced 22.5% in SURMOUNT-1 (PMID: 35658024). Retatrutide outperformed both — in a shorter trial with a smaller sample.
Beyond weight loss, the Phase 2 trial showed approximately 82% reduction in liver fat at the 12 mg dose. That finding opened MASH (metabolic dysfunction-associated steatohepatitis) as a major second indication — a condition with enormous unmet medical need and few approved treatments.
Phase 3: The TRIUMPH program
The TRIUMPH Phase 3 program launched in 2023 with at least seven trials across multiple indications. The first to report results was the knee osteoarthritis trial (NCT05882045) in February 2026. Those results exceeded the Phase 2 data:
- 28.7% average body weight loss at the 12 mg dose over 48 weeks
- 75.8% reduction in knee pain (WOMAC pain score)
- Significant improvements in knee function and physical performance
The primary obesity trial (NCT06383390) is still enrolling and running. Results are expected mid-to-late 2026. That trial will form the backbone of Eli Lilly's NDA submission for the obesity indication.
| Trial | Drug | Weight Loss | Duration |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 14.9% | 68 weeks |
| SURMOUNT-1 | Tirzepatide 15 mg | 22.5% | 72 weeks |
| Retatrutide Phase 2 | Retatrutide 12 mg | 24.2% | 48 weeks |
| TRIUMPH (OA) | Retatrutide 12 mg | 28.7% | 48 weeks |
Important caveat: the retatrutide Phase 2 trial enrolled 338 participants vs 1,961 in STEP 1 and 2,539 in SURMOUNT-1. Smaller trials often produce larger effect sizes. The TRIUMPH primary obesity trial will be the definitive comparison.
For the full trial tracker and enrollment guide, see every retatrutide clinical trial tracked. For the Phase 2 deep dive, see what 24% weight loss means for the field. For the full weight loss data breakdown, see retatrutide weight loss results.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
How retatrutide compares to other obesity medications
The obesity medication landscape has a clear hierarchy based on mechanism complexity. Each generation adds receptor targets and produces greater weight loss. Retatrutide sits at the top.
| Compound | Mechanism | Best Result | FDA Status | Liver Fat |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 14.9% (68 wk) | Approved | Moderate |
| Tirzepatide | GLP-1 + GIP | 22.5% (72 wk) | Approved | Moderate |
| Survodutide | GLP-1 + Glucagon | 19.2% (46 wk) | Phase 3 | Significant |
| Retatrutide | GLP-1 + GIP + Glucagon | 28.7% (48 wk) | Phase 3 | ~82% reduction |
Each additional receptor addresses a complementary biological mechanism. GLP-1 reduces appetite. GIP improves metabolic processing and fat utilization. Glucagon increases energy expenditure. The combined effect is not simply additive — it is a more comprehensive metabolic intervention than any single or dual agonist can deliver.
Two caveats apply. First, these are not head-to-head trials. Differences in trial design, population, and duration make direct comparisons imperfect. Second, semaglutide and tirzepatide have years of real-world safety data across millions of patients. Retatrutide's safety profile is still being established in Phase 3.
Detailed comparison analyses:
- Retatrutide vs Ozempic: Triple agonist vs the GLP-1 standard
- Retatrutide vs Wegovy: Which is better for weight loss?
- Retatrutide vs Mounjaro: Triple agonist vs dual agonist compared
- Retatrutide vs Tirzepatide: What the research shows
- Retatrutide vs Tirzepatide: Which next-gen peptide wins?
- Retatrutide vs Survodutide: The two glucagon-activating compounds compared
Structured comparison database pages:
- Semaglutide vs Retatrutide
- Tirzepatide vs Retatrutide
- Retatrutide vs Tirzepatide vs Semaglutide (three-way)
Retatrutide for weight loss
Who the trials enrolled
The Phase 2 trial enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. People with type 2 diabetes were excluded from the Phase 2 obesity arm but are being studied in a dedicated TRIUMPH trial.
The Phase 3 knee osteoarthritis trial enrolled adults with BMI 35 or higher and confirmed knee osteoarthritis. That specific population may respond differently from the general obesity population. The primary TRIUMPH obesity trial data, expected mid-to-late 2026, will provide the most broadly applicable evidence.
Expected timeline and weight loss trajectory
Based on Phase 2 data, the weight loss trajectory breaks down roughly as follows:
- Weeks 1 to 12: Dose escalation phase. GI side effects are most common during this window. Early weight loss begins, typically 3-5%.
- Weeks 12 to 24: Reaching maintenance dose. Weight loss rate accelerates significantly.
- Weeks 24 to 48: Primary weight loss period. Most of the total effect occurs in this window.
- Beyond 48 weeks: Weight loss continues to slow as the body adapts. Weight maintenance becomes the primary therapeutic goal.
The dose escalation schedule is important for tolerability. In Phase 2, participants started at 2 mg and escalated every 4 weeks, reaching the 12 mg maintenance dose at approximately week 20. Rushing escalation increases GI side effects without improving weight loss outcomes.
Side effect profile for weight loss candidates
The Phase 2 trial reported the following side effects at the 12 mg dose:
| Side Effect | Rate at 12 mg | Notes |
|---|---|---|
| Nausea | ~45% | Most common; improves with time and titration |
| Diarrhea | ~24% | Lower than semaglutide rates |
| Vomiting | ~18% | Dose-dependent; resolves at maintenance dose |
| Constipation | ~16% | Lower than semaglutide rates |
| Dysesthesia | ~5% | Tingling or numbness — unique to retatrutide |
Dysesthesia — abnormal skin sensation (tingling, burning, or numbness) — is the one side effect that distinguishes retatrutide from all other GLP-1 class medications. It appeared in about 5% of participants at the highest dose, is believed to be glucagon receptor-related, and was generally mild and temporary. It does not occur with semaglutide or tirzepatide.
A critical safety note: the Phase 2 trial enrolled 338 people. Semaglutide has been used by millions. Rare side effects only emerge in large populations. Phase 3 data from thousands of participants will tell a much more complete safety story than Phase 2 can.
For complete side effect analysis: retatrutide side effects: what Phase 2 data actually shows. For the full weight loss data analysis: retatrutide for weight loss: what the Phase 3 data shows.
How to get retatrutide in 2026
Clinical trials (the only legitimate option)
As of March 2026, retatrutide is not FDA-approved and cannot be legally prescribed. The only way to access pharmaceutical-grade retatrutide is through enrollment in a TRIUMPH Phase 3 trial.
The TRIUMPH program is actively enrolling participants at medical centers across the United States and internationally. To find trial sites and check eligibility:
- Visit ClinicalTrials.gov
- Search "retatrutide" or "LY3437943" or "TRIUMPH"
- Filter by "Recruiting" status
- Review eligibility criteria (most require BMI 30 or higher, or 27 or higher with comorbidities)
- Contact the listed study sites directly
Important caveat: in a randomized controlled trial, you may receive a placebo rather than the active drug. Participation involves regular clinic visits, blood draws, and monitoring. Discuss any clinical trial with your physician before enrolling.
For a step-by-step walkthrough: how to enroll in a retatrutide clinical trial in 2026.
Research peptide vendors
Some online vendors sell products labeled as retatrutide for "research purposes only." These are not FDA-regulated. There is no independent verification of purity, potency, or sterility. Retatrutide is a structurally complex molecule. Producing it to pharmaceutical standards requires specialized manufacturing capabilities that most research chemical vendors do not have.
We do not recommend self-administering investigational compounds obtained outside of clinical trials, particularly when FDA-approved alternatives with established safety profiles exist and are currently available.
Future prescription access and cost expectations
Once FDA-approved, retatrutide will be available by prescription from any licensed healthcare provider. Based on the TRIUMPH timeline, the earliest realistic approval is mid-to-late 2027. A 2028 approval is the more conservative and arguably more realistic expectation.
On cost: Eli Lilly has not announced pricing. Based on tirzepatide's launch at approximately $1,060 per month and the added manufacturing complexity of a triple agonist, industry analysts estimate $1,000-$1,500 per month at launch. Insurance coverage will be the biggest real-world variable. Manufacturer savings programs and compounding availability will depend on market conditions at the time of approval.
For the cost analysis: retatrutide cost: what to expect when it hits the market. For the FDA timeline breakdown: retatrutide FDA approval timeline and retatrutide approval date: what to expect in 2026-2027.
Retatrutide and other conditions
Liver disease: MASH and NAFLD
MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) may be the most important secondary indication for retatrutide. The Phase 2 trial showed approximately 82% reduction in liver fat at the highest dose — a finding no other GLP-1 class medication has matched. This is directly attributable to glucagon receptor activation, which promotes hepatic fat oxidation independently of weight loss.
Eli Lilly is running a dedicated MASH trial as part of TRIUMPH. The condition has enormous unmet need and limited treatment options. If Phase 3 data confirms the Phase 2 liver fat findings, retatrutide could become a leading treatment for MASH — potentially before or alongside the obesity approval.
For the full analysis: retatrutide for liver health: MASH and NAFLD data explained.
Sleep apnea
The link between obesity and obstructive sleep apnea (OSA) is direct and well-established. Significant weight loss reliably improves or resolves OSA in many patients. TRIUMPH includes a dedicated sleep apnea trial tracking apnea-hypopnea index (AHI) reduction as a primary endpoint.
Tirzepatide's SURMOUNT-OSA trial showed approximately 50% reduction in AHI at the highest dose. Retatrutide, producing greater weight loss, may match or exceed that. Cardiovascular benefits from OSA resolution are an additional consideration for high-risk patients.
For what current data shows: retatrutide and sleep apnea: what the trials show.
Cardiovascular outcomes
TRIUMPH includes a dedicated cardiovascular outcomes trial, but it will run the longest of all the TRIUMPH arms — likely through 2028 or beyond. Semaglutide's SELECT trial established cardiovascular benefit as a class effect for GLP-1 medications (20% reduction in major adverse cardiovascular events in high-risk patients). Retatrutide's glucagon component may provide additional cardiovascular benefits via direct thermogenic and lipid metabolism effects, but this remains speculative until outcomes data is available.
The compound page tracks all ongoing indications: retatrutide compound profile.
Get retatrutide updates as they happen.
Phase 3 results, FDA decisions, access guides — delivered weekly. No spam. Unsubscribe anytime.
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
All retatrutide content on this site
This hub aggregates every retatrutide article, comparison, and reference page on Peptide Nerds. Each article below also links back to this hub.
Core guides
- Retatrutide for Weight Loss: What the Phase 3 Data Shows
- Retatrutide Weight Loss Results: Full Data Breakdown
- Retatrutide Before and After: What to Realistically Expect
- Retatrutide Complete Guide
- Retatrutide Mechanism of Action: How the Triple Agonist Works
Clinical trials and FDA timeline
- Every Retatrutide Clinical Trial Tracked (2026)
- How to Enroll in a Retatrutide Clinical Trial
- Retatrutide Phase 2 Results: What 24% Weight Loss Means
- Retatrutide FDA Approval Timeline
- Retatrutide Approval Date: What to Expect in 2026-2027
Side effects and safety
Cost and access
Condition-specific coverage
Comparisons (editorial)
- Retatrutide vs Ozempic
- Retatrutide vs Wegovy
- Retatrutide vs Mounjaro: Triple Agonist vs Dual Agonist
- Retatrutide vs Tirzepatide: What the Research Shows
- Retatrutide vs Tirzepatide: Which Next-Gen Peptide Wins?
- Retatrutide vs Survodutide: The Two Next-Gen Weight Loss Drugs
Comparison database pages
- Semaglutide vs Retatrutide
- Tirzepatide vs Retatrutide
- Retatrutide vs Tirzepatide vs Semaglutide (three-way)
Compound reference pages
- Retatrutide compound profile
- Retatrutide benefits
- Retatrutide dosage guide
- Retatrutide side effects (compound page)
- Retatrutide FAQ
Frequently asked questions
When will retatrutide be FDA-approved?
Retatrutide is currently in Phase 3 clinical trials under the TRIUMPH program. The first Phase 3 results were reported in February 2026. Based on standard FDA review timelines, the earliest realistic approval is mid-to-late 2027. A more conservative estimate is 2028. Both depend on when Eli Lilly submits their NDA and whether the FDA grants Priority Review.
How much weight can you lose on retatrutide?
Phase 2 trials showed an average of 24.2% body weight loss at the 12 mg dose over 48 weeks — the largest weight loss ever recorded in a controlled clinical trial at that time. The first Phase 3 trial (in patients with obesity and knee osteoarthritis) reported 28.7% weight loss. For a 250-pound person, that is roughly 60-72 pounds. Individual results vary and Phase 3 primary obesity data is still pending.
Is retatrutide better than Ozempic?
Clinical data strongly suggests retatrutide produces significantly more weight loss than semaglutide (24-29% vs 14.9%). The triple receptor mechanism — adding GIP and glucagon activation on top of GLP-1 — provides additional metabolic benefits including increased energy expenditure and an 82% reduction in liver fat. That said, semaglutide has years of real-world safety data and is available now. Retatrutide is still investigational.
What are retatrutide side effects?
The most common side effects in Phase 2 trials were gastrointestinal: nausea (~45%), diarrhea (~24%), vomiting (~18%), and constipation (~16%). These are consistent with the GLP-1 drug class and typically improve with the slow dose escalation schedule. A unique signal is dysesthesia — tingling or numbness — reported in about 5% of participants at the highest dose, likely related to glucagon receptor activation. This is not seen with semaglutide or tirzepatide.
How much will retatrutide cost?
Eli Lilly has not announced pricing. Based on the tirzepatide pricing model and the added complexity of a triple agonist, industry analysts estimate $1,000-$1,500 per month at launch without insurance. Insurance coverage will be the biggest variable. Manufacturer savings programs and compounding pharmacy availability will depend on market dynamics after approval.
Can you get retatrutide right now?
Retatrutide is only available through clinical trials. It is not FDA-approved and cannot legally be prescribed. Some online vendors sell research chemicals labeled as retatrutide, but these products are unregulated with no verified purity or safety. The only legitimate access is through enrollment in a TRIUMPH trial at ClinicalTrials.gov.
Is retatrutide a GLP-1?
Retatrutide activates the GLP-1 receptor as one of its three targets, so it is technically a GLP-1 receptor agonist — but it is more accurately described as a triple agonist or GIP/GLP-1/glucagon agonist. The GLP-1 component is the foundation; the GIP and glucagon components are what make it distinct from compounds like semaglutide.
What makes retatrutide different from tirzepatide?
Tirzepatide is a dual agonist targeting GLP-1 and GIP. Retatrutide adds a third receptor: glucagon. The glucagon component increases energy expenditure and promotes liver fat oxidation — addressing the energy-out side of the equation in a way tirzepatide does not. This is why retatrutide produced 24.2% weight loss in Phase 2 vs tirzepatide's 22.5% in SURMOUNT-1, and why it reduced liver fat by ~82% vs moderate reduction with tirzepatide. The two compounds have never been directly compared in a head-to-head trial.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM, 2023. PMID: 37385275
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. PMID: 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022. PMID: 35658024
- NCT05882045: Retatrutide in Adults with Obesity and Knee Osteoarthritis (Phase 3). ClinicalTrials.gov
- NCT06383390: Retatrutide for Obesity — TRIUMPH Primary Trial. ClinicalTrials.gov
- Boehringer Ingelheim. Survodutide Phase 2 obesity trial. NEJM, 2024. PMID: 38587239
Get the Peptide Starter Kit (free)
A quick-start guide covering GLP-1 peptides, dosing basics, side effect management, and what to discuss with your doctor.
Medical disclaimer: The information on this page is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Retatrutide is an investigational compound not approved by the FDA for any indication. Always consult a qualified healthcare provider before starting any medication or peptide protocol. Individual results vary. See our full medical disclaimer.